Search for Associate Director for Clinical Research and Holden Chair

 
Search for Associate Director for Clinical Research and Holden Chair
ABOUT THIS POSITION
                                           1
      CHANGING MEDICINE. CHANGING LIVES.

Search for Associate Director
for Clinical Research and
Holden Chair
Search for Associate Director for Clinical Research and Holden Chair
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
2   SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH
Search for Associate Director for Clinical Research and Holden Chair
ABOUT THIS POSITION
                                                                                                  3
                                                             CHANGING MEDICINE. CHANGING LIVES.

Contents
About this search.........................................4

Holden Comprehensive
Cancer Center...............................................9
  History....................................................................10
  Today......................................................................14
  Holden Family Support.....................................16
  Organization and Leadership.........................18
  Research Programs........................................... 22
  Cores and Shared Resources......................... 29

University of Iowa Health Care.............45

UI Carver College of Medicine..............59

UI Hospitals and Clinics..........................75

Health Sciences Campus....................... 85

University of Iowa..................................... 91

The Iowa City Community....................97
Search for Associate Director for Clinical Research and Holden Chair
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
4   SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH

    About this
    Position
    The Holden Comprehensive Cancer Center (HCCC) at The
    University of Iowa is seeking an outstanding clinician-
    investigator to serve as the associate director for clinical
    research and to direct the Roland W. Holden Family Program
    in Experimental Therapeutics. The successful candidate will
    also serve as the Holden Family Chair.

     As the associate director for clinical research       The ideal candidate will also have familiarity
     of an NCI-designated Comprehensive Cancer             with both laboratory and clinical aspects of
     Center Center, the successful candidate will be       cancer experimental therapeutics and drug
     expected to provide leadership and integrate          development, investigator-initiated and
     all therapeutically related translational and         cooperative group clinical trials, knowledge
     clinical cancer research taking place within the      of regulatory guidelines and procedures, and
     institution, and also contribute to establishing      familiarity with NCI-designated Cancer Center
     external collaborations. The successful               operations.
     candidate will have an MD or MD/PhD degree,
     with a strong record of publication and funding,      The successful candidate will have their
     including external peer-reviewed funding, in          primary academic appointment in a clinical
     clinical cancer research and experimental             department at The University of Iowa Carver
     therapeutics. Experience in a multi-disciplinary      College of Medicine. A leadership role in the
     setting, experience in program development            Division of Hematology, Oncology, and Blood
     in an academic medical center, commitment             and Marrow Transplantation in the Department
     to diversity in the workplace, and excellent          of Internal Medicine is available based on the
     communication and leadership skills are               interest and qualification of the applicant.
     required.
Search for Associate Director for Clinical Research and Holden Chair
ABOUT THIS POSITION
                                                                                                       5
                                                                  CHANGING MEDICINE. CHANGING LIVES.

The HCCC received NCI-designation       In addition, a number of cancer type
in 1999 and comprehensive               specific muliti-disciplinary oncology
designation from the NCI in 2000.       groups (MOGs) have been developed
It has undergone successful             and are active in both clinical and
competitive renewal of this             research efforts. The HCCC has a
designation twice since that time.      robust Clinical Trials Support Core
The HCCC is organized in two            that includes 35 full-time staff who
different dimensions. The formal        assist in protocol development,
research programs of the HCCC are       management, and the conduct of
based on scientific discipline and      trials. The Clinical Trials Support
include cancer immunology and           Core also supports bedside to bench
immunotherapy, cancer signaling and     translational research including
experimental therapeutics, cancer       the prospective clinical registries of
genetics and gell growth, tumor         the HCCC. These are known as the
imaging, free radical cancer biology,   Molecular Epidemiology Resources
and cancer epidemiology.                (MERs), work closely to the HCCC
                                        Tissue Procurement Core and
                                        biobanks, and have enrolled over
                                        4,500 subjects in a variety of cancer
                                        types.
Search for Associate Director for Clinical Research and Holden Chair
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
                6    SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH

Role and Responsibilities
The Holden Comprehensive Cancer Center associate
director for clinical research will lead the clinical and
translational research efforts of the cancer center. This
includes providing administrative oversight of the clinical
research infrastructure, clinical research collaborative
efforts, clinical and translational research pilot grant
programs, serving as a mentor to junior investigators
and determining use of funds dedicated to clinical
cancer research. The associate director will serve on the
HCCC Leadership Committee and Research Executive
Committee, and will chair the Clinical Research Leadership
Committee.

The associate director for clinical research will supervise
the assistant directors for clinical research. Together,
they will oversee the Clinical Trials Support Core, Clinical
Trials Development, Support and Monitoring Office,
Protocol Review Committee and the Data and Safety
Monitoring Committee as well as the 12 cancer-specific
multidisciplinary oncology groups.
Search for Associate Director for Clinical Research and Holden Chair
ABOUT THIS POSITION
                                                                                                            7
                                                                     CHANGING MEDICINE. CHANGING LIVES.

Endowed Positions and Programs
The Holden Endowment to support Experimental Therapeutics was established in 2000 to support
research geared towards advancing knowledge of cancer and application of this knowledge to the
discovery and development of new cancer therapeutics. This research is expected to include the
design and synthesis of novel chemicals and testing of active agents in humans.

The endowment consists of two components.:

Holden Family Chair
This fund supports a chair in the University of Iowa Roy J. and Lucille A. Carver College of Medicine for
the Director of the Roland W. Holden Family Program for Experimental Cancer Therapeutics.

Roland W. Holden Family Program for Experimental Cancer Therapeutics
The Program itself is supported by the Roland W. Holden Family Endowed Fund.

Support for the clinical research infrastructure of the Holden Comprehensive Cancer Center comes
from other sources so support from the Roland W. Holden Family Program for Experimental Cancer
Therapeutics can be directed towards specific research projects in Experimental Cancer Therapeutics.

Dr. Raymond Hohl was the founding Director of the Program. Dr. Hohl’s efforts focused on the RAS
pathway and novel approaches to targeting the isoprene intermediates in the cholesterol biosynthetic
pathway. His efforts included extensive collaborations with synthetic chemists in the Department of
Chemistry as well as a broad range of investigators across the Cancer Center. The next recipient of the
Holden Chair will be expected to leverage the infrastructure and contributions developed by Dr. Hohl
while also applying their own research expertise to goals of the Holden Program in Experimental
Therapeutics.
Search for Associate Director for Clinical Research and Holden Chair
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
      8      SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH

Search Committee

          K A RL W. T H O M A S , M D                                      GA RY ROS EN T HA L , MD

          Chair                                                            Director, Iowa Institute for Clinical and
          Executive Vice Chair, Department of Internal                     Translational Science
          Medicine                                                         Professor of Internal Medicine
          Professor of Internal Medicine
          karl-thomas@uiowa.edu                                            gary-rosenthal@uiowa.edu

          MO H A M M E D M . M I L H E M , M B BS                          YAT IN V YA S , MD, PHD

          Deputy Director for Clinical Cancer Care,                        Director, Division of Pediatric Hematology and
          Holden Comprehensive Cancer Center                               Oncology
          Associate Professor of Internal Medicine                         Professor of Pediatrics

          mohammed-milhem@uiowa.edu                                        yatin-vyas@uiowa.edu

          K I M B E RLY K . L E S L I E , M D                              JA MES C. WA L K ER, PHD

          Chair and Department Executive Officer,                          Associate Vice President for Research
          Department of Obstetrics and Gynecology
                                                                           james-walker@uiowa.edu
          kimberly-leslie@uiowa.edu

          MI C H A E L H E N RY, P H D                                     B RIA N K . L IN K , MD

          Deputy Director for Research, Holden                             Director, Clinical Trials Support Core, Holden
          Comprehensive Cancer Center                                      Comprehensive Cancer Center
          Associate Professor of Molecular Physiology                      Professor of Internal Medicine
          and Biophysics
          michael-henry@uiowa.edu                                          brian-link@uiowa.edu

          ALIASGER SALEM, PHD                                               PA LOMA H. G IA N GRA N DE , PHD

          Lyle and Sharon Bighley Professor of                              Associate Professor of Internal Medicine
          Pharmaceutical Sciences and Leader, Cell
          Signaling and Experimental Therapeutics                           paloma-giangrande@uiowa.edu
          Program, Holden Comprehensive Cancer
          Center
          aliasger-salem@uiowa.edu
Search for Associate Director for Clinical Research and Holden Chair
About the Holden
Comprehensive
Cancer Center
Search for Associate Director for Clinical Research and Holden Chair
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
10   SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH

     Holden
     Comprehensive
     Cancer Center
     Efforts to form a comprehensively organized program
     in cancer began in the 1970s when former Dean John
     W. Eckstein, MD charged the College of Medicine’s
     Committee on Cancer with the responsibility of reviewing
     and developing research, demonstration, and education
     programs in cancer.

     Richard L. DeGowin, MD began the effort by            Since 1980, the Cancer Center has experienced
     working with faculty members in the College’s         tremendous growth and achieved the highest
     of Medicine, Nursing, Dentistry, Pharmacy             level of recognition status given by the National
     and Liberal Arts and Sciences and after much          Cancer Institute—comprehensive—in
     work, a plan was implemented for the creation         2000. To reflect this achievement, and in
     of a more organized cancer program at the             recognition of a landmark, $25 million gift
     university. Following presentation to the             from four generations of the Holden family of
     Board of Regents, State of Iowa, in 1980 the          Williamsburg, Iowa, the Cancer Center was
     new program was conferred special “center             renamed the Holden Comprehensive Cancer
     designation, ” and DeGowin became the Cancer          Center.
     Center’s first director.
ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER
                                                 11
            CHANGING MEDICINE. CHANGING LIVES.
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
               12      SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH

Timeline
  1980
 The University of Iowa cancer program is conferred special
 “center” status by the Iowa Board of Regents.

 Richard L. DeGowin named director.

          1981                                                                                                             1998
                                                                                                        George J. Weiner, MD, appointed
          The Cancer Center received a three-year CancerCenter                                            director of the Cancer Center.
          Support Grant from the National Cancer Institute.

                                                                              1993
          The grant was not renewed.

                                   With the support of a generous gift from the Pappajohn
                               family of Des Moines, the John and Mary Pappajohn Clinical
                                       Cancer Center opened, providing a multidisciplinary
                                 approach to state-of-the-art patient care. This effort was
                                                  coordinated by Richard D. Williams, MD.

                                                 1988
                                                 University of Iowa, University of
                                                 Iowa College of Medicine and                                     1995
         1986                                    University of Iowa Hospitals and
                                                 Clinics leadership develop plans                                 University of Iowa
                                                 for expanded laboratory research                                 President Mary Sue
  Cancer Information                             initiatives and construction of new
      Service opens.                                                                                              Coleman, PhD, College
                                                 clinical care facilities.                                        of Medicine Dean Robert
                                                                                                                  Kelch, MD and R. Edward
                                                                                                                  Howell, director and
                                                                                        1994                      CEO of the UI Hospitals
                                                                                                                  and Clinics—all recently
                                                                                                                  appointed—reinforce
                                                The NCI provided funds for restructuring the Cancer               institutional commitments
                                                Center through a P20 Cancer Center Planning Grant.                to support and strengthen
                                                         This effort was led by Richard G. Lynch, MD.             the Cancer Center.
                                             Robert B. Wallace, MD, was appointed as director of the
                                                                                    Cancer Center.
ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER
                                                                                                                          13
                                                                             CHANGING MEDICINE. CHANGING LIVES.

1999
The Cancer
Center
submitted
a Cancer                2002
Center
Support                 Completion of
                        the new Roland
                                                                 2007                            2011                    2014
Grant
application             and Ruby Holden                          New image guided                NCI-                    Dr, Raymond Hohl,
to the                  Cancer Research                          center for radiation            designation as a        associate director
National                Laboratories.                            therapy opens.                  comprehensive           for clinical research
Cancer                                                                                           cancer center           and Holden Chair,
Institute.              Iowa receives its                        Renewal of $11.9                following               moves to Penn State
                        first Specialized                        million Specialized             competitive             University as director
                        Program of Research                      Program of                      review with             of the Penn State
                        Excellence (SPORE)                       Excellence (SPORE)              a score of              Hershey Cancer
                        Grant—the Iowa/                          grant for lymphoma              “outstanding.”          Center.
                        Mayo Lymphoma                            research.
                        SPORE.

                2001                                                       2008
                                                                           Center receives National Outstanding Achievement Award from the
                                                                           Commission on Cancer for providing superior care to patients and
                Construction
                                                                           families.
                begins on
                the Holden
                                                                           Center Iowa teams up with several agencies to provide housing,
                Cancer
                Research
                Laboratories
                                                  2005                     transportation and medical assistance to cancer patients devastated
                                                                           by the floods and tornadoes in Iowa.
                in the new
                                                  NCI-designation as a
                Medical
                                                  comprehensive cancer center
                Education
                                                  renewed following competitive
                and Research
                                                  review.
                Facility.

                                         2004
                                         Iowa Consortium for Comprehensive Cancer Control launched,
                                         providing coordinated cancer control for Iowans.

        2000
        The National Cancer Institute conducts a site visit of the Cancer Center in January.

        The National Cancer Institute confers “NCI-designated Cancer Center” status in July.

        The Cancer center receives a landmark, $25 million gift from four generations of the Holden family
        of Williamsburg, Iowa and is renamed Holden Cancer Center.

        The Roland W. Holden Family Program for Experimental Therapeutics was established and
        Dr. Raymond Hohl, was named the Roland W. Holden Family Chair for Experimental Cancer
        Therapeutics.

        Holden Cancer Center achieves the highest level of recognition—comprehensive status given by
        the National Cancer Institute and is renamed Holden Comprehensive Cancer Center.
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
              14    SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH

The Center Today
Holden Comprehensive Cancer              • Free Radical and Cancer Biology
Center remains dedicated to bringing     • Tumor Imaging                                While research is conducted in
world-class research and cancer care                                                    laboratories throughout the University
to Iowa, the Midwest, and beyond.        • Cancer Epidemiology                          of Iowa campus, the Roland and Ruby
                                         • Cancer Genomics and Cell Growth              Holden Cancer Research Laboratories
The matrix center now spans the                                                         allow the Center to integrate many
University of Iowa and includes          Each of these programs is focused on           researchers in close proximity to each
approximately 180 formal Cancer          a cancer-relevant scientific discipline,       other.
Center members and many additional       is translational, and includes
physicians, investigators and other      members from several colleges and              Outreach to the people of Iowa is
staff from 36 related university         diverse backgrounds.                           an important component of the
departments and six colleges, as well                                                   Center’s activities. Holden provides
as the University of Iowa Hospitals      The Holden Comprehensive                       information through its Cancer
and Clinics and the University of Iowa   Cancer Center is also organized                Information Service to patients, their
Children’s Hospital.                     based on cancer type through the               families, and health professionals.
                                         Multidisciplinary Oncology Groups              In addition, there are a number of
Research at Holden Comprehensive         (MOGs). The MOGs are responsible               cancer support groups that meet
Cancer Centeris organized into six       for coordinating multidisciplinary             regularly in local communities. The
research programs:                       clinical care through tumor boards,            Center also includes many patients
• Cancer Immunology and 		               multidisciplinary clinics, etc.                in its active program of Phase I and
  Immunotherapy                          They also serve as the focus for               Phase II clinical trials.
                                         development of innovative clinical
• Cancer Signaling and Experimental      trials.
  Therapeutics
ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER
                                                                                                           15
                                                                     CHANGING MEDICINE. CHANGING LIVES.

Holden Comprehensive Cancer Center Statistics

C LI N I C AL AC T I V I T Y             C L I N ICA L FACIL IT IES A N D S PACE    RES EA RCH A N D S PACE

             154,232                                      37                                     $74.2
   Total visits to UI Health Care with               Exam rooms in                  Million in total annual cancer-related
     primary diagnosis of cancer                    the Cancer Clinic                           research funding

               31,372                                      3                                       $44
      Unique patients treated with                  Consult rooms in                  Million in current endowments in
      primary diagnosis of cancer                   the Cancer Clinic                       support of the mission

              48,288                                       2                                        221
              Total visits in the                 Treatment Rooms in                        Open clinical trials for
                cancer clinic                       the Cancer Clinic                         cancer patients

                 3,615                                    32                                     3,289
     Admissions for patients with a                  Chairs in the                            Patients enrolled in
      primary diagnosis of cancer                 chemotherapy suite                              clinical trials

                3,800                                      8                                        189
    New cancer patients diagnosed                    Beds in the                        Cancer Center members in 36
      at UI Hospitals and Clinics                 chemotherapy suite                    departments and six colleges

             20,400                               >146,000                                            6
            Radiation oncology                     Net square feet of                        Research Programs
           treatments delivered                 clinical oncology space                         in the Center

               14,639                                     74                                         10
         Chemotherapy sessions               Inpatient beds on three units             Core Facilities supported by the
              delivered                       with a dedicated pharmacy                        Cancer Center

                    117                                   14                                          4
        Bone marrow transplants             Beds in the Adult Leukemia and             Core Facilities supported by the
         (106 adult, 11 pediatric)           Bone Marrow Transplant Unit                  Lymphoma SPORE grant

                8,283                                     31                                    33,953
         Contacts to the Cancer           Bone bone marrow transplant and              Square feet of research space in
          Information Service                hematology oncology beds                   Holden Research Laboratories
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
               16    SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH

Holden Family Support
Through years of visionary support for the Holden                RES EA RCH
Comprehensive Cancer Center at the University of Iowa,
                                                                 Cutting-edge research, new cancer investigators, and
the Holden family has helped establish the UI as a major
                                                                 studies that have translated laboratory discoveries into
center for cancer research, patient care, and education.
                                                                 innovative patient treatment options.
The Holden Comprehensive Cancer Center was so named
in 2000, when four generations of the Holden family made
                                                                 The Clinical Trials Support Core, which include trials
a landmark gift of $25 million to support what was then the
                                                                 that come from our own labs, collaboration with other
University of Iowa Cancer Center. In the 13 years since the
                                                                 cancer centers, and partnerships with biotechnology and
Holden gift, world-class research scientists, physicians,
                                                                 pharmaceutical companies. Treatments that would not
and other health care professionals have worked tirelessly
                                                                 otherwise be available in Iowa are available to our patients
to advance research that helps prevent, detect, and treat
                                                                 because of these trials.
cancer for our patients.
                                                                 PAT IEN T S ERV ICES A N D CA RE
The Holden family gift was made in honor of the late
Roland W. Holden, who died in 1995. Holden founded               The UI Palliative Care Service—a team of nurses, social
Holden Foundation Seeds Inc., a corn seed research and           workers, chaplains and physicians that assists terminally ill
genetics company based in Williamsburg, Iowa, 30 miles           patients and their families. This interdisciplinary program
west of Iowa City, in 1937. His family chose to celebrate his    provides emotional and spiritual support and help in
legacy by supporting research and treatment that may             planning for care outside the hospital, as well as pain
eventually cure the disease that took his life.                  control and symptom management.

Contributors to the $25 million gift included Ruby Holden;
Ronald, Arlene, and Kathy Holden; Susan and David
McCurry; Karol Holden; Mary Ann and Curtis Blythe; and
the Roland and Ruby Holden Foundation.

The gift, one of the largest received for UI Health Care
initiatives, has supported a full range of critical programs
within the Holden Comprehensive Cancer Center, including:
ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER
                                                  17
            CHANGING MEDICINE. CHANGING LIVES.

                         The Holden family of Williamsburg, Iowa.
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
                        18   SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH

                                                               HCCC Executive Board
                                                                   Jean Robillard, MD
                                                            Vice President for Medical Affairs

Organization                                                           Director
                                                                   George Weiner, MD

                                                            Deputy Director for Research
                                                                 Michael Henry, PhD

                               Executive Director of Development                                 Internal and External
                                   Sarah Russett, UI Foundation                                     Advisory Boards

                                                                Associate Director for
                                                                  Clinical Research

              Assistant Director for                                                       Assistant Director for Clinical
        Multidisciplinary Clinical Research                                                        Research Services
             Mohammed Milhem, MBBS                                                                  Daniel Vaena, MD
                                                                                        Carlie Etscheidt (Administrative Director)

     Multidisciplinary        Multidisciplinary                                                                    Clinical Trials
    Oncology Groups            Oncology Group                                     Protocol Review and              Support Core
                              Research Support
      Carmen Tilman              Coordinator                                          Monitoring                   Brian Link, MD
    (Board Coordinator)        Julianna Kennedy                                                                       (Director)

        Protocol                                       Clinical Trials                                            Clinical Trials
   Development and               DSM Chair           Data Management                Clinical Trials                                    Informatics Support
                                                                                 Regulatory Manager               Translational         Systems Specialist
    Monitoring Chair            Daniel Berg, MD           Manager                                               Research Manager
  Michael Goodheart, MD                                 Mary Schall                Marian Andersen                                          Inez Mattke
                                                                                                                  Laura Jacobus

       Protocol                                     Clinical Research            Regulatory Associate         Translational Research
                                                    Specialists                  T. Kriegel                   Assistants
   Development and                                  M. Arnold (90%)                                           C. Hamlin
  Monitoring Manager                                R. Arthur                    Financial Analyst            A. Janoski
       Gary Rick                                    M. Frees                     B. Franzwa                   T. Knutson
                                                    J. Geick Miller              J. Gallagher                 M. Brumm
  Protocol Writer and                               K. Parrott                                                S. Rosazza
  Safety Officer                                    J. Wegmann                   Cancer and Leukemia
  M. Rosenquist                                     P. Zehr                      Group B Coordinator          Biospecimen Collection
                                                                                 C. Halvorsen                 Technician
  Protocol Management                               Clinical Research                                         J. Cook-Granroth
  Assistant                                         Associates                   National Surgical
  A. Childs                                         S. Gillen                    Adjuvant Breast              Data Manager
                                                    J. Schlabaugh                and Bowel Project            S. Grimm (temp)
                                                                                 Coordinator
                                                    Clinical Research            C. Robertson
                                                    Assistants
                                                    J. de la Garza               Clerk III
                                                    S. Teahen                    L. Johnson (75%)

                                                    Clinical and Data
                                                    Management Research
                                                    Specialist
                                                    A. Tricot

                                                    Data Managers
                                                    A. Marlof
                                                    A. Schultz
                                                    A. Capper
                                                    A. Ulin

                                                    Medical Assistant II
                                                    J. Larson
ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER
                                                                                                         19
                                                                    CHANGING MEDICINE. CHANGING LIVES.

Leadership
George J. Weiner, MD
Director, Holden Comprehensive Cancer Center
George Weiner MD, is an active translational cancer investigator who has been on the faculty at
the University of Iowa since 1989. He is Director of the Holden Comprehensive Cancer Center
(HCCC), Professor of Internal Medicine, C.E. Block Chair of Cancer Research, and a faculty
member in the Interdisciplinary Program in Immunology at the University of Iowa.

Administratively, Dr. Weiner was appointed Director of the HCCC on December 1, 1998, and
led the HCCC to recognition as an NCI-designated comprehensive cancer center in 2000.
This designation was renewed in 2005 and 2011. Dr. Weiner was served in a number of
leadership positions at the state and national level including the following.
• Chair, NCI subcommittee A also known as the Cancer Center Parent Committee (2007-
  2009). He chaired site visits for the NCI at 8 cancer centers.
• Vice President / President Elect, Association of American Cancer Institutes (2013-present).
• President, Iowa Cancer Consortium (2003-present)
• Chair, Governmental Affairs Committee, American Society of Hematology
  (2008-2012)
• Co-Chair, Science Policy and Governmental Affairs Committee,
  American Association for Cancer Research (2012-present)
• Chair of External Advisory Boards for 3 NCI designated cancer
  centers.
• PI of the Iowa/Mayo Lymphoma SPORE (2002-present)
• Co-Chair, C-Change initiative on Comprehensive Cancer Control
• Member, CTAC - NCI Clinical and Translational Research
  Advisory Committee (2012-present)

Dr. Weiner’s research focuses on understanding the
mechanisms of action of anti-cancer monoclonal antibodies,
and on development of novel approaches to immunotherapy
of lymphoma. He has been continually funded by the
NCI since 1991. Dr. Weiner’s research extends from basic
laboratory investigation to clinical trials. He is the holder of
four patents with a number of others pending, and was the
first to demonstrate Toll Like Receptor 9 agonists could be used
successfully as immune adjuvants in tumor immunization. He
also has made major contributions to our understanding of the
mechanisms of action responsible for the anti-tumor activity of
monoclonal antibodies.
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
                 20     SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH

GAI L A . BI SHOP, P H D                     E L I Z A B E TH CHRIS CHIL L ES , PHD         MICHA EL D. HEN RY, PHD

Associate Director for Basic Research        Associate Director for Population Science      Deputy Director for Research

Dr. Gail Bishop, appointed associate         Elizabeth Chrischilles, the Marvin A.          Dr. Henry serves as deputy director
director for basic research in 2004,         and Rose Lee Pomerantz Chair in                for research. This important position
advises the HCCC director on                 Public Health, and director, Health            is supported by institutional funds.
issues related to the basic science          Effectiveness Research Center, was             He has focused his efforts on new
programs, including allocation of            appointed as the HCCC associate                initiatives and special projects
research space, and resources,               director for population sciences in            including developing the overall
and membership in the research               2007.                                          Molecular Oncology Initiative. A
programs. Bishop’s role is to                                                               major focus of this effort is improving
coordinate and assure the quality of         In this role, Dr. Chrischilles is              tissue collection, annotation and
the basic science research programs          charged with enhancing the HCCC’s              distribution through the Tissue
of the Center, to provide advice on          population science activities including        Procurement Core/Biospecimens
faculty recruitment in basic science         epidemiology, prevention, community            Initiative including identification of a
areas, formulate program policy, and         health, public policy and outcomes             software package described above.
overseeing the use of basic science          analysis. She provides leadership to           He has also worked on integrating
shared facilities in consultation with       the research programs considered               the molecular pathology group
the associate director for research          primarily population science                   into the HCCC. This has included
infrastructure. Bishop works with            programs and provides advice and               promoting meetings of the director
the HCCC director to encourage               guidance to HCCC members relative              of the Molecular Pathology Division,
translation of basic advances to             to population science activities               Dr. Aaron Bossler, with MOGs and
the clinic. As associate director for        within the HCCC. She also has                  medical oncologists to assess
basic science, Dr. Bishop reviews all        the responsibility of encouraging              ongoing needs for new actionable
applications for HCCC membership.            population science activities in the           molecular tests. In late 2013, the
She is a member of both the HCCC             other research programs.                       molecular pathology group received
Executive Committee and Associate                                                           CLIA certification for sequencing
Director’s Committee. The research           Dr. Chrischilles is a member of the            capabilities of 50 cancer-related
programs that are primarily focused          HCCC Executive Committee and the               genes that are now being used
on basic cancer research (Cancer             Associate Directors Committee.                 for both clinical care and clinical
Genomics and Cell Growth, and                                                               research. Dr. Henry also chairs
Free Radical Cancer Biology) report                                                         the monthly Research Executive
formally to her. Dr. Bishop also                                                            Committee meeting which includes
provides advice related to the basic                                                        all of the Program Leaders and Co-
laboratory research taking place in                                                         Leaders.
the other four research programs.
ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER
                                                                                                                          21
                                                                               CHANGING MEDICINE. CHANGING LIVES.

DAVI D M . LU B A RO F F, P H D                  M O HA MMED M. MIL HEM, MD                     CHRIS TOPHER L AUB EN T H AL , MBA

Associate Director for Research Infrastructure   Deputy Director for Clinical Cancer Services   Associate Director for Administration

David Lubaroff, Ph.D., has served                Dr. Milhem has been a faculty                  The associate director for
as associate director for research               member at the University of Iowa,              administration, plans, directs, and
infrastructure since 1998. In his role,          and a member of the Holden                     coordinates, the administrative
he is responsible for coordinating               Comprehensive Cancer Center since              operations and activities of the HCCC
the shared research resources and                2007.                                          including both research and clinical
working closely with the directors                                                              activities. Laubenthal facilitates
of these facilities to assure they are           He has a remarkable record of                  interactions with the UI Hospitals
serving the needs of HCCC members.               accomplishments related to clinical            and Clinics and the Carver College
He serves on the faculty advisory                research team leadership in that               of Medicine to enhance clinical and
committees of the majority of shared             period of time, and is an emerging             basic research productivity. He serves
research resources supported                     leader in the field of clinical cancer         as liaison with other departments,
by the HCCC. He also monitors                    research both institutionally and              colleges, and outside organizations.
usage of shared research resources               nationally.                                    He works closely with senior
and makes recommendations to                                                                    leadership to assure coordination and
the shared resource resources                    Dr. Milhem is deputy director for              communication related to cancer
based on their performance. Dr.                  clinical cancer services in hte Holden         oriented clinical service, research
Lubaroff explores the need for and               Comprehensive Cancer Center. In                and education. He manages all fiscal
development of new shared research               this role he leads the development             activities, including coordination of
resources by periodically surveying              of better clinical services to help the        annual budget process (operating
HCCC membership to document                      cancer center achieve its goals and to         and capital), analysis of income
shared facility activities and unmet             facilitate clinical cancer research and        and expenditures, projections for
needs. His responsibilities include              activities. He is leading many efforts         annual budget requests, fiscal
developing, coordinating and                     to improve workflow for clinician              reports, equipment and supplies,
maintaining research educational                 researchers and improve processes.             maintenance, and assisting with and
programs for members including                                                                  overseeing the grants management
seminars and conferences, and a                                                                 process. He is administratively
program of visiting research scientists                                                         responsible for the administration
and lecturers. He coordinates the                                                               of the grant application process and
monthly HCCC Forum. Lubaroff works                                                              the conduct of research activities in
closely with HCCC administrative                                                                the HCCC including oversight of the
staff in oversight of shared research                                                           shared core resources. This includes
resource activities. Dr. Lubaroff is                                                            approximately $54.7 million in direct
a member of the HCCC Executive                                                                  costs of which approximately 14.4
Committee and Associate Directors                                                               million is managed directly by the
Committee                                                                                       Cancer Center.
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
               22    SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH

Research Programs

                     Cancer Immunology and Immunotherapy

AB OUT TH E P ROGRA M                                                                    L EA DERS HIP

The Cancer Immunology and Immunotherapy Program consists of faculty
investigators who are linked by common research interests in the functioning
of the immune system, and how that system can be manipulated to help
prevent or treat cancer and complications of cancer. The investigators in this
program are working on problems that extend from fundamental molecular
questions to those involving how recent advances in basic immunology can be
translated into clinical utility for the treatment of cancer.                            ZUHAIR K.               GAIL A.
                                                                                         BALLAS, MD              BISHOP, PHD
                                                                                         Professor of Internal   Professor of
Although many of investigators in the Cancer Immunology and                              Medicine                Microbiology and
Immunotherapy Program are pursuing related questions, the individual                                             Internal Medicine
research programs are diverse, allowing researchers in this program to attack
basic biologic issues, and develop new clinical therapies, from many angles.
Model systems being studied range from an evaluation of signaling properties
of T and B cells, to increasing the efficacy of vaccines and immunotherapy
in living animals, through the conduct of novel clinical trials related to
cancer immunotherapy. Clinical applications, as a direct result of more basic
investigations, have arisen from within the group and it is expected that this will
continue.

Because of the diversity of research interests reflected within the membership
of the Cancer Immunology and Immunotherapy Program, a wide range of
technologies and approaches are available to investigators. Each of our
investigators benefits from interactions with others in the program, as well
as members of additional Cancer Center programs, resulting in a synergism
yielding new insights, perspectives, and collaborative efforts.
ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER
                                                                                                                  23
                                                                           CHANGING MEDICINE. CHANGING LIVES.

                           Cancer Signaling and Experimental
                           Therapeutics Program

    ABOUT THE P RO G RA M                                                                L EA DERS HIP

    The overall organizational goal of the Cancer Signaling and Experimental
    Therapeutics Program is to facilitate the application of recent advances in
    our understanding of cell signaling, cell cycle control, and apoptosis, to the
    development of new pharmacologic approaches to cancer prevention and
    therapy.

    Investigators in this program are working on problems that extend from
                                                                                         ALIASGER K.            YATIN M.
    fundamental molecular questions involving signaling pathways to those                SALEM, PHD             VYAS, MD
    involving the design of novel compounds based on our growing knowledge of            Associate Professor    Professor of
                                                                                         of Pharmaceutics       Pediatrics
    molecular aspects of cell biology. Such laboratory scientists collaborate with
    other members of the Program who are clinical investigators with a broad
    range of backgrounds and expertise in performing innovative clinical cancer
    trials.

    The program includes basic and clinical investigators from multiple
    departments at the University of Iowa, and has members who have primary
    appointments in the Colleges of Medicine, Pharmacy, and Liberal Arts.

Kimberly Leslie, MD at work in her laboratory.
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
               24    SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH

                     Tumor Imaging Program

AB OUT TH E P ROGRA M                                                                         L EA DERS HIP

The goal of the Imaging Program is to foster interdisciplinary research that
integrates modern medical imaging techniques into basic, translational, and
clinical cancer research studies. The methodologies will include computed
tomography (CT), magnetic resonance imaging (MRI), ultrasound, positron
emission tomography (PET), gamma scintigraphy, optical imaging, and
autoradiography. Metabolic imaging extends the capability of imaging well
beyond anatomy. It includes imaging blood flow, vascular permeability,                        MICHAEL                JOHN
metabolic rates (glucose, oxygen, DNA synthesis, protein synthesis, membrane                  GRAHAM, MD,            BUATTI, MD
                                                                                              PHD                    Professor and Chair,
synthesis), receptor distribution and density (estrogen, testosterone,                        Professor of           Radiation Oncology
somatostatin), apoptosis, angiogenesis, cell trafficking, and reporter gene                   Radiology
activation. Members of the imaging program are working in all these areas. The
importance of having an Imaging Program is that it brings these investigators
together to collaborate, and share ideas, imaging strategies, and data analysis
methods.

The Imaging Program has the following specific areas of focus:

• Metabolic assessment of response
  to therapy
• Iodine symporter as a reporter
  gene and as a novel therapy
• Cell trafficking
• Development of new
  radiopharmaceuticals
• Development of novel analysis
  methodologies

                                                                                         Eric Hoffman, MD works with students and
                                                                                         staff in the Magnetic Resonance Research Facility.
ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER
                                                                                                           25
                                                                     CHANGING MEDICINE. CHANGING LIVES.

                    Free Radical and Cancer Biology
                    Program

ABOUT TH E P RO G RA M                                                              L EA DERS HIP

For many years it has been recognized that many agents used to treat
cancer (i.e., radiation and chemotherapy agents) cause oxidative stress that
contributes to the mechanism by which they kill cancer cells as well as damage
normal tissues. Recently, it is becoming increasingly clear that metabolic
oxidation/reduction (redox) reactions are also altered in cancer vs. normal
cells. The current consensus is that cancer cells may exist in a chronic state
of metabolic oxidative stress that may represent a significant underlying           DOUGLAS R.            FREDERICK E.
mechanism contributing to malignancy. A unifying goal of the investigators          SPITZ, PHD            DOMANN, JR.,
                                                                                    Professor of          PHD
in the Free Radical Cancer Biology Program is to utilize a comprehensive            Radiation Oncology    Professor of
understanding of redox biology to develop novel biochemical rationales                                    Radiation Oncology
for improving cancer therapy taking advantage fundamental differences in
oxidative metabolism between cancer vs. normal cells.

The researchers in the Free Radical Cancer Biology Program (FRCBP) focus
on studying the biological consequences of inherent differences in redox
metabolism between cancer vs. normal cells to determine the role that
redox reactions play in cancer phenotypic changes relevant to cell growth,
differentiation, signal transduction, metastasis, functional molecular imaging,
and cancer therapy. A unifying goal of the program is to utilize a comprehensive
basic science understanding of cancer cell redox biology to develop novel
biochemical rationales for improving cancer therapy. Three overlapping
themes exist within the program.

Theme 1                                  Theme 2                                    Theme 3
Understanding the role of redox          Understanding the role of redox            Exploring the role of oxidative stress
biochemistry in regulation of genetic    regulation in cell biology. Within this    in cancer therapy outcomes. Within
and epigenetic gene expression           theme are focus groups exploring           this theme are focus groups exploring
pathways relevant to cancer biology.     the effects of intracellular redox         the role of manipulating oxidative
Within this theme are focus groups       environmental changes on the               stress to improve cancer therapy
exploring redox and gene expression      cell cycle, and on invasion and            as well as using imaging of oxidative
globally, as well as gene expression     metastasis.                                metabolism as an approach to
of key redox molecules such as                                                      monitor and guide therapy.
glutathione, thioredoxin, SOD, and
AP2.
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
                  26     SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH

                         Cancer Epidemiology Program

   AB OUT TH E P ROGRA M                                                                     L EA DERS HIP

   The overall goal of the Cancer Epidemiology Program is to save lives by
   increasing our understanding of what causes cancer, promoting cancer
   prevention behaviors and early detection and treatment, and developing
   improved diagnostic tests and treatments. When cancer cannot be prevented,
   we are also interested in research that will extend the quantity and quality of
                                              life for the cancer survivor.
                                                                                             CHARLES F. LYNCH, MD, PHD
                                              A major strength of the Cancer                 Professor of Epidemiology and Pathology

                                              Epidemiology Program is its extension
                                              beyond the walls of the medical
                                              center, as its primary research
                                              population is residents across the
                                              state of Iowa. This is based on the role
                                              played by the University of Iowa in
                                              public health across Iowa, including
Barcey Levy, MD, PhD                          cancer epidemiology. Members of
                                              the Cancer Epidemiology Program
    are responsible for the State Health Registry of Iowa (SHRI), Iowa’s statewide
    cancer surveillance program that is part of the Surveillance, Epidemiology,
    and End Results (SEER) Program of the National Cancer Institute (NCI). This
    resource allows researchers in the Cancer Epidemiology Program to perform
    outstanding population-based cancer research. Information gained from these
    studies can then be applied to other states and other populations.

   The Cancer Epidemiology Program has three focus areas.
   • Cancer Etiology
   • Cancer Health Services and Outcomes
   • Cancer Prevention and Control
ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER
                                                                                                               27
                                                                         CHANGING MEDICINE. CHANGING LIVES.

                     Cancer Genomics and Cell Growth Program

ABOUT TH E P RO G RA M                                                                  L EA DERS HIP

Research in the Cancer Genomics and Cell Growth Program focuses on genetic
and molecular events controlling normal versus malignant cell proliferation,
differentiation and survival. The overall goal of the program is to define
biologically significant genetic and molecular alterations in tumor cells so that
information can be used to more effectively detect and treat human cancers.
There are two major overlapping themes within the umbrella of the Progam’s
research.                                                                               DAWN E.               SIEGFRIED
                                                                                        QUELLE, PHD           JANZ, MD, DSC
                                                                                        Associate Professor   Professor of
Theme 1                                                                                 of Pharmacology       Pathology
Genomic organization and cancer gene expression/analysis

Theme 2
Cell growth, differentiation, survival and transformation.

Major accomplishments of the Cancer Genomics and Cell Growth Program
over the past funding period are best reflected by its identification and
characterization of novel cancer genes and/or biomarkers, development of
novel animal tumor models to discover and assess cancer gene function in
vivo, and increasing collaboration as demonstrated by coalescence of program
members into effective working groups. Key examples of intraprogrammatic
research collaborations include a) studies revealing the role of chromatin
binding proteins (such as RPA, DNA polymerases, HP1, transcription factors)
in gene expression and how that impacts the cancer phenotype, b) studies
defining basic mechanisms of viral infection and replication, and how that
leads to cell transformation, and c) the discovery and subsequent functional
analysis of novel genetic pathways of carcinogenesis. There are numerous
past and present productive collaborations both between members of the
Program, and with members of other Cancer Center programs. There are
currently 16 NIH and NCI funded projects involving multiple Program members
and/or HCCC members from other programs serving as co-Investigators. The
program consists of 36 members from 12 departments (8 basic science and 4
clinical departments) and 5 Colleges. Peer-reviewed, research funding for this
program totals $8,449,398 with $2,583,657 coming from the NCI.

Members of the Program have 300 cancer-related publications with nearly
30% collaborative publications (17% intra-programmatic, 12% inter-
programmatic) during the last grant period.
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
28   SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH
ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER
                                                                                        29
                                                 CHANGING MEDICINE. CHANGING LIVES.

Core Facilities and Shared Resources
The Holden Comprehensive Cancer Center provides Center members with access to the services
and resources of our core facilities. The facilities provide quality products and services that enhance
the research efforts of Cancer Center investigators to foster basic and translational research.
Members of the Cancer Center with peer-reviewed, funded projects are the primary beneficiaries of
these core resources.

The core facilities within the Holden Comprehensive Cancer Center are funded by a combination
of funding from the Cancer Center Support Grant, Institutional support, other University of
Iowa sources and charge-back for services. David Lubaroff, PhD, associate director for research
infrastructure oversees these cores.

Clinical Trials Support Core
• Clinical Trials Data                                • Clinical Trials Translational
• Clinical Trials Regulatory                          • Protocol Development and Monitoring

Cancer Center Support Grant
• Clinical Trials Support Core                        • Gene Transfer Vector Core
• Bioinformatics Core                                 • High Throughput Screening Core
• Biostatistics Core                                  • Population Research Core
• Central Microscopy Research Facility                • Radiation and Free Radical Research Core
• DNA Core                                            • Small Animal Imaging
• Flow Cytometry Core                                 • Tissue Procurement Core

Lymphoma SPORE Grant                                  Other Resources
• Biospecimens                                        • Molecular Pathology Resource
• Biostatistics and Bioinformatics                    • Proteomics Resource
• Clinical Research                                   • Drug Discovery Resources
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
              30    SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH

Clinical Trials Support Core

PUR P OSE                                 S E RV I C E S                                                    L EA DERS HIP

The Clinical Trials Support Core          • Routing of protocols through the University of Iowa
(CTSC) provides administrative              Institutional Review Board or Western Institutional
services and data management                Review Board and the appropriate regulatory
to all members of the Holden                committees
Comprehensive Cancer Center who
                                          • Providing expertise in coordination of clinical trial
conduct clinical studies.The CTSC is        activities (recruitment of patients, determining 		             BRIAN K. LINK,
a shared resources and is designed          eligibility, obtaining consent, scheduling procedures,          MD
to facilitate the conduct of high-                                                                          Director
                                            coordinating patient care needs, managing data
quality clinical and translational          collection)
cancer research and is composed
                                          • Serving as liaison to pharmaceutical companies,
of dedicated staff with expertise in
                                            governmental regulatory agencies and other outside
protocol management and study
                                            vendors
coordination.
                                          • Budget writing and billing
                                          • Assisting investigators with annual reviews, protocol
                                            modifications and reporting of adverse events
                                          • Providing assistance with collection and processing
                                            blood and tissue samples for translational research
                                          • Listing of all current clinical trials in the clinical trials
                                            booklet

                                          The Holden Comprehensive Cancer Center is also
                                          an active participant of seven National Cooperative
                                          Groups and investigators within the Center enroll over
                                          550 patients on clinical research studies each year. The
                                          National Cooperative Group Trials that are involved within
                                          the Holden Comprehensive Cancer Center include:

                                          • Cancer and Acute Leukemia Group B (ALLIANCE)
                                          • National Surgical Adjuvant Breast Project (NSABP)
                                          • Eastern Cooperative Oncology Group (ECOG)
                                          • Collaborative Ocular Melanoma Study (COMS)
                                          • Children’s Oncology Group (COG)
                                          • Gynecological Oncology Group (GOG)
                                          • Radiation Therapy Oncology Group (RTOG)

                                          The Clinical Trials Support Core is currently staffed by
                                          approximately 32 staff members.
ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER
                                                                                                          31
                                                                    CHANGING MEDICINE. CHANGING LIVES.

Bioinformatics Core

PUR POS E                               S E RV ICES                                                      L EA DERSH IP

To provide bioinformatics support for   Assistance is available on all types of projects, ranging
Cancer Center investigators in the      from clinical trials to basic science experiments. Early
design, data collection/archiving and   consultation during the design of a study may be
analysis of high-throughput genomics    especially beneficial.
assays in cancer research projects.     • Consultation on study design, selection of technology
                                          platforms and formulation of hypotheses                        THOMAS L.
                                                                                                         CASAVANT, PHD
                                        • Specification of appropriate software tools and 		             Director
                                          methods for data analysis
                                        • Database creation (DNA sequence, RNA expression,
                                          proteomics, etc.)
                                        • Protocol development
                                        • Information technology consultation
                                        • Data and experiment analysis
                                        • Assistance in preparation of manuscripts
                                        • Education and training

Biostatistics Core

PUR POS E                               S E RV ICES                                                      L EA DERSH IP

To provide statistical support for      Assistance is available on all types of projects, ranging
Cancer Center investigators in the      from clinical trials to basic science experiments. Early
design, analysis, and reporting of      consultation during the design of a study may be
cancer research projects.               especially beneficial.
                                        • Consultation on study design, selection of outcome
                                          variables and formulation of hypotheses
                                                                                                         BRIAN J. SMITH,
                                        • Specification of appropriate methods of data analysis          PHD
                                                                                                         Director
                                        • Protocol development
                                        • Generation of randomization schedules
                                        • Data analysis
                                        • Assistance in preparation of manuscripts
                                        • Education and training.
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
              32    SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH

Central Microscopy Research Facility

PUR POS E                                S E RV I C E S                                                  L EA DERS HIP

The Central Microscopy Research          • Scanning electron microscopy
Facility provides instrumentation
                                         • Transmission electron microscopy
and technical assistance to research
programs involving the use of            • Light microscopy
scanning and transmission electron       • Laser capture microdissection
microscopy, light and confocal
                                         • Confocal microscopy                                           RANDY A.
microscopy, scanning probe                                                                               NESSLER, BGS,
microscopy, freeze fracture and x-ray    • Multi-photon microscopy                                       MBA
                                                                                                         Director
microanalysis.                           • Cryo-techniques
                                         • Elemental analysis
                                         • Atomic force microscopy
                                         • Bioluminescence microscopy

                                         The facility also provides all solutions, supplies and
                                         training necessary for investigators involving microtomy
                                         including:

                                         • Specialized staining and
                                           embedding techniques
                                         • Negative staining
                                         • Metal coating
                                         • Autoradiography
                                         • Cryo-fixation
                                         • Cryomicrotomy
                                         • Enzyme-cytochemistry
                                         • Immunocytochemistry
                                         • Morphometry                                              Scanning electron microscopy.

                                         • Stereology
ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER
                                                                                                         33
                                                                   CHANGING MEDICINE. CHANGING LIVES.

DNA Core

PUR POS E                               S E RV ICES                                                     L EA DERSH IP

The purpose of the DNA Facility is      • DNA Microarrays (Affymetrix GeneChip system and
to provide a centralized resource for     Custom DNA microarrays using slide format)
access to state-of-the-art equipment
                                        • Real-time PCR
used in DNA sequence and transcript
analysis. The DNA Facility strives to   • DNA Sequencing (Sanger dideoxy sequencing using
provide high quality services with        capillary-based instruments and genomic sequencing
                                                                                                        KEVIN
rapid turnaround and support their        using the Roches 454 and ABI SOLID instruments                KNUDTSON, PHD
services with well trained personnel                                                                    Director
                                        • Synthetic Oligonucleotide
that are able to consult with users
                                        • Molecular biology computing including custom
on how they may best utilize their
                                          nucleic acid analysis, microarray analysis and genomic
services. The DNA Facility continues
                                          sequence assembly/analysis.
to evaluate and update their services
so they remain cutting-edge, and        • Bioanalyzer to assess nucleic acid quality and quantity
provide new services as necessary to
continue to meet the needs of Center
investigators.

                                                             Kevin Knudtson, PhD gives a tour of the core during a STEM
                                                             education program.
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
                     34    SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH

    Flow Cytometry Core

    PU R POS E                                     S E RV I C E S                                                L EA DERS HIP

    The Flow Cytometry Core is located             In addition to identification and isolation of various cell
    in the Eckstein Medical Research               populations using antibodies, flow cytometry can analyze:
    Building (EMRB). The facility has one          • Cell proliferation response to drugs or treatments, such
    magnetic-based and six laser-based               as those used in chemotherapy
    instruments whose major purpose
    is the identification and isolation of         • Cell physiological properties, such as calcium flux and
                                                     pH                                                          ZUHAIR K.
    various cell populations. The laser-                                                                         BALLAS, MD
    based instruments accomplish                   • DNA content and integrity                                   Director
    this by the use of antibodies to               • Transfection markers such as GFP and mCherry
    which various colors or dyes have
    been attached and are directed at              Offline data analysis using FlowJoTM, CellquestTM, and
    molecules known to exist on the                ModFITTM can be done through the facility’s system of
    cell surface. By using several colors          networked computers. Investigators equipped with IBM
    attached to different antibodies,              or Mac-compatible PCs can perform analysis at their
    one can identify and purify cells that         laboratories or offices by accessing data through the
    express any given configuration of             Facility’s dedicated 1.5 terabyte file server.
    various molecules.
                                                   The facility provides scientific and technical personnel
                                                   who are available for consultation in designing
                                                   experimental protocols. Cell preparation protocols and
                                                   publication quality output are available upon request.

A student is trained on instrumentation in the core.
ABOUT THE HOLDEN COMPREHENSIVE CANCER CENTER
                                                                                                           35
                                                                     CHANGING MEDICINE. CHANGING LIVES.

Gene Transfer Vector Core

PUR POS E                                 S E RV ICES                                                     L EA DERSH IP

The Gene Vector Core assists              The University of Iowa Carver College of Medicine GTVC
researchers interested in developing      brings together investigators interested in developing and
and using viral vector construction.      using, viral and non-viral vectors for gene transfer with
The core utilizes molecular biology       specialists in the area of vector construction by:
techniques to engineer and produce        • Consultation with the principal investigator to plan
viral and non-viral vectors in              and develop transfer vectors to fit individual projects       BEVERLY L.
quantities necessary for gene transfer      requirements                                                  DAVIDSON, PHD
in research experiments or preclinical                                                                    Director
studies. Core staff works closely with    • Assist investigators with troubleshooting existing
investigators to plan and develop           projects
gene transfer vectors to fit individual   • Design and development of novel vectors
project requirements.                     • Develop novel methods of virus production such as
                                            the RapAdTM System for adenovirus production
                                          • Generation of RNAi expression vectors
                                          • Purify, concentrate, and perform quality control on
                                            preparations of recombinant adenovirus, adeno-
                                            associated virus (AAV), moloney murine retrovirus,
                                            lentivirus, baculovirus, and vaccinia virus
                                          • Maintain and distribute standard cell lines and stocks
                                            of recombinant reporter viruses
UNIVERSITY OF IOWA HOLDEN COMPREHENSIVE CANCER CENTER
               36    SEARCH FOR HOLDEN FAMILY CHAIR AND DIRECTOR FOR CLINICAL RESEARCH

High Throughput Screening Core

PUR POS E                                  S E RV I C E S                                               L EA DERS H IP

Initiated by the Vice President            A robotic platform is available with 8-independent
for Research and the Holden                channels and a 384 channel pipetting head. A liquid
Comprehensive Cancer Center                handling robot is also equipped with on-board incubators
through collaboration with multiple        (4 plates) and two positions for incubation/chilling of
departments, and housed in                 stock solutions.
the College of Pharmacy, the
                                                                                                        MENG WU, PHD
High Throughput Screening,                 An integrated Perkin Elmer Envision Multimode high           Director
Target Validation and Biomarker            speed plate readed for use with detection is equipped
Identification Resource is aimed at        with filters and monochromators. The plate reader,
pharmacologic characterization of          controlled through the integrated software, supports
new molecular entities in enzyme,          fluorescence, time-resolved flouorescence, fluorescence
receptor and cell-based systems,           polarization, time-resolved FRET, absorbance and
including potency, intrinsic activity,     specialized screening technologies including AlphaScreen,
selectivity, specificity, and off-target   DELFIA and LANCE. The Envision is also equipped with
effects. This activity also includes       two photomultipliers and a dedicated uHTS laster for high
the identification and validation/         speed AlphaScreen.
qualification of biomarkers for
target activation/inhibition, proof-       The laboratory is also equipped with a five-color Roche
of-concept, efficacy and safety. An        Lightcycler 480 II system, allowing for secondary
example is the use of high throughput      confirmation of hits binding to a purified target using
screening for the discovery of novel       differential scanning fluorimtetry.
pre-therapeutic lead molecules
directed at neurological applications.     Two small molecular libraries are currently available. The
Strong leadership and multiple pilot       Spectrum Library consists of 2,320 structurally diverse
grants have led to a large number of       compounds including marketed and experimental drugs
collaboration exploratory projects in      and natural products. A larger collection houses 50,000
the very short time that the center        small molecules representing a wide swath of chemical
has been functional.                       space, optimized to be “drug-like.”

                                           Management of compound library plates and screening
                                           data is done through M-Screen, a web-accessed
                                           academic database for analysis and curation.
You can also read